Evaluation of models for predicting drug–drug interactions due to induction

Bibliography

• Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162(9):985-92
   PubMed Web of Science ®Google Scholar
• Ripp SL. Induction of drug-metabolizing enzymes: contrasting roles in detoxification and bioactivation of drugs and Xenobiotics. In: Elfarra A, editor, Advances in bioactivation research. Springer Science + Business Media, New York, NY; 2008
   Google Scholar
• Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005;94(6):1169-86
   PubMed Web of Science ®Google Scholar
• Moore LB, Parks DJ, Jones SA, Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275(20):15122-7
   PubMed Web of Science ®Google Scholar
• Frye RF. Probing the world of cytochrome P450 enzymes. Mol Interv 2004;4(3):157-62
   PubMed Web of Science ®Google Scholar
• Spaans E, van den Heuvel MW, Schnabel PG, Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol 2002;58(6):423-9
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Kish M, Boldt S, Obach RS. Cytochrome P450 3A4 messenger RNA is a more reliable marker than CYP3A4 activity for detecting PXR-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 2010;38:1605-11
   PubMed Web of Science ®Google Scholar
• Parkinson A, Hurwitz A. Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. Gastroenterology 1991;100(4):1157-64
   PubMed Web of Science ®Google Scholar
• Almond LM, Yang J, Jamei M, Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 2009;10(4):420-32
   PubMed Web of Science ®Google Scholar
• Chu V, Einolf HJ, Evers R, In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 2009;37(7):1339-54
   PubMed Web of Science ®Google Scholar
• Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling. FDA/Center for Drug Evaluation and Research 2006
   Google Scholar
• Mills JB, Rose KA, Sadagopan N, Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004;309(1):303-9
   PubMed Web of Science ®Google Scholar
• Aninat C, Piton A, Glaise D, Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006;34(1):75-83
   PubMed Web of Science ®Google Scholar
• Hariparsad N, Carr BA, Evers R, Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 2008;36(6):1046-55
   PubMed Web of Science ®Google Scholar
• Sinz M, Kim S, Zhu Z, Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7(4):375-88
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29(11):1499-504
   PubMed Web of Science ®Google Scholar
• Persson KP, Ekehed S, Otter C, Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res 2006;23(1):56-69
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008;36(1):137-45
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Boldt S, Kish M, Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008;36(9):1971-4
   PubMed Web of Science ®Google Scholar
• Shou M, Hayashi M, Pan Y, Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 2008;36(11):2355-70
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Hurst S, Plowchalk D, Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009;37(8):1658-66
   PubMed Web of Science ®Google Scholar
• Ripp SL, Mills JB, Fahmi OA, Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 2006;34(10):1742-8
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman R, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35(4):275-91
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Maurer TS, Kish M, A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008;36(8):1698-708
   PubMed Web of Science ®Google Scholar
• Smith DA, Dickins M, Fahmi OA, The time to move cytochrome p450 induction into mainstream pharmacology is long overdue. Drug Metab Dispos 2007;35(4):697-8
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril 2004;81(5):1187-93
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35(2):246-55
   PubMed Web of Science ®Google Scholar
• Einolf HJ. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 2007;37(10-11):1257-94
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6(2):140-8
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5(2):211-23
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Zhang G, Kenny JR, Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009;37(6):1259-68
   PubMed Web of Science ®Google Scholar
• Kato M, Chiba K, Horikawa M, Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 2005;20(4):236-43
   PubMedGoogle Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006;316(1):336-48
   PubMed Web of Science ®Google Scholar
• van Giersbergen PL, Dingemanse J. Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. J Clin Pharmacol 2005;45(1):42-7
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. SO – clinical pharmacokinetics 2004;43(15):1089-115
   PubMed Web of Science ®Google Scholar
• Olling M, Mensinga TT, Barends DM, Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999;20(1):19-28
   PubMed Web of Science ®Google Scholar
• Ucar M, Neuvonen M, Luurila H, Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004;59(12):879-82
   PubMed Web of Science ®Google Scholar
• Janne TB, Klaus TO, Mikael O, Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996;37(3):253-7
   PubMed Web of Science ®Google Scholar
• Hellriegel ET, Arora S, Nelson M, Robertson P Jr. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol 2002;42(4):450-60
   PubMed Web of Science ®Google Scholar
• Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002;71(1):46-56
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Desager JP, Pauwels S, Harvengt C. Lack of effect by nifedipine on hepatic mixed function oxidase in man. Fundam Clin Pharmacol 1991;5(3):193-201
   PubMed Web of Science ®Google Scholar
• Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther 1989;249(2):638-45
   PubMed Web of Science ®Google Scholar
• Reidenberg P, Glue P, Banfield CR, Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 1995;58(3):279-87
   PubMed Web of Science ®Google Scholar
• Backman JT, Olkkola KT, Ojala M, Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996;37(3):253-7
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Vega JM, Zhao J, Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001;41(5):573-81
   PubMed Web of Science ®Google Scholar
• ActosR Product Label. Deerfield, IL: Takeda Pharmaceuticals, America, Inc.; 2009
   Google Scholar
• Ma JD, Nafziger AN, Rhodes G, Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos 2006;34(5):783-5
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman SM, Kearns GL. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J Clin Pharmacol 1999;39(6):613-18
   PubMed Web of Science ®Google Scholar
• Lang CC, Jamal SK, Mohamed Z, Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol 2003;55(6):588-90
   PubMed Web of Science ®Google Scholar
• Nafcillin Product Label. Princeton, NJ: Sandoz, Inc.; 2008
   Google Scholar
• Polk RE, Brophy DF, Israel DS, Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45(2):502-8
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivisto KT, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68(6):592-7
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42(9):819-50
   PubMed Web of Science ®Google Scholar
• Harris RZ, Inglis AM, Miller AK, Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol 1999;39(11):1189-94
   PubMed Web of Science ®Google Scholar
• Avandia Product Label. Research Triangle Park, NC: GlaxoSmithKline; 2008
   Google Scholar
• GlaxoSmithKline Study Register. Available from: http://www.gsk-clinicalstudyregister.com/ : Study No: 102130; Research Triangle Park, NC: GlaxoSmithKline, 2006
   Google Scholar
• Rezulin product label. Parsippany, NJ: Parke Davis Pharmaceuticals, Ltd; 1999
   Google Scholar